Manufacturer: CycloLabIndia enquiries: +91 9391852431 · sales@akiralabs.com

Applications

Analytical areas where CD-Screen and CD-Screen-IEC columns may support method development.

Parent cyclodextrin analysis

Parent cyclodextrins such as alpha-, beta- and gamma-cyclodextrin can present limited retention on many conventional reversed-phase systems. CD-Screen methods may be investigated when cyclodextrin-focused selectivity is required. Applicability must be demonstrated for the target analyte set and detector.

Residual parent cyclodextrins

Modified cyclodextrin products may contain residual underivatized starting material. Monitoring this residual fraction can support raw-material characterization, process understanding and quality control. The method should distinguish the parent material from the broader derivative distribution and sample-matrix components.

Degradation products

Forced-degradation and stability studies may generate related carbohydrate fragments or altered derivatives. A CD-Screen-based method can be explored as part of a stability-indicating strategy, provided specificity, sensitivity and mass-balance expectations are assessed.

Statistically substituted cyclodextrins

Statistically substituted materials contain populations that differ in substitution number and position. Chromatographic profiles can therefore represent component distributions rather than a single pure compound. Method development should focus on repeatable profile resolution and meaningful system-suitability measures.

Drug-formulation analysis

Cyclodextrins are used as formulation excipients to alter solubility, stability and delivery characteristics. Assays may need to quantify the cyclodextrin or derivative in the presence of an active ingredient and other excipients. Sample preparation, matrix effects and detector response require careful evaluation.

SBECD and ionic derivatives

CD-Screen-IEC is intended for ionic cyclodextrin derivatives and is relevant to SBECD analysis. Potential goals include degree of substitution, component distribution and selected impurities such as BCD, HBSA and DBSA. Method transfer should include instrument-equivalence checks and fresh system suitability.

Method-development considerations

Developers should assess mobile-phase composition, ionic strength where relevant, pH compatibility, flow rate, temperature, injection volume, sample solvent, detector compatibility and column equilibration. Samples should be clarified and filtered where appropriate. A method intended for release or stability testing requires validation for specificity, precision, accuracy, range, linearity, robustness and solution stability as applicable.

Do not adopt exact chromatographic conditions without an approved manufacturer method or a method independently optimized and validated for the intended sample.